Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis

Ryan, Caitriona; Kelleher, John F.; Fagan, M. F.; Rogers, S.; Collins, Paul M.; Barker, Jonathan; Allen, Michael; Hagan, Richard; Renfro, Lindsay A.; Kirby, Brian

doi:10.1111/ced.12323

Cited by 34 publications

(35 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[33][34][35][36][37][38][39][40][41][42][43] For all significant associations, except TLR9 (rs352139) and LY96 (rs11465996), similar tendencies were observed for ORs for each of the anti-TNF agents (data available on request). To our knowledge, this is one of the largest cohorts for evaluation of response in patients treated with ustekinumab 44,45 and the second largest for evaluation of anti-TNF; only a Canadian study (also involving treatment primarily for psoriatic arthritis) had more patients.…”

Section: Study Populationmentioning

confidence: 61%

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

et al. 2017

View full text Add to dashboard Cite

Section: Study Populationmentioning

confidence: 61%

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

et al. 2017

View full text Add to dashboard Cite

“…For psoriasis, a variety of biomarkers have been suggested to be useful for the prediction of treatment outcome [22][23][24][25][26]. With respect to the GST system, it has been shown that the clinical response to efalizumab correlates with glutathione peroxidase activity in the blood cells, suggesting that high hydroperoxide levels are involved in psoriasis persistence [27].…”

Section: Discussionmentioning

confidence: 99%

Val/Val glutathione-S-transferase P1 polymorphism predicts nonresponders in psoriasis patients treated with fumaric acid esters

Gambichler

Susok

Zankl

et al. 2016

Pharmacogenetics and Genomics

View full text Add to dashboard Cite

Fumaric acid esters (FAE) are beneficial in the treatment of psoriasis. However, about a third of psoriasis patients do not respond to FAE. We aimed to determine whether glutathione-S-transferase (GST) M1 and GSTP1 polymorphisms are associated with treatment outcome in psoriasis patients treated with FAE. We studied 84 psoriasis patients who were treated with FAE for 3 months. FAE nonresponders were defined as having psoriasis area and severity improvement index less than 50% after 3-month therapy. GSTM1 genotyping for gene deletion and GSTP1 exon 5 105 Ile→Val polymorphisms were assessed using a high-resolution melting analysis. A dropout rate of 23.8% (20/84) was found; 25% (16/64) were FAE nonresponders. We observed 42 (84/50%) patients with G 9STM1*0 homozygous alleles and 42 (84/50%) patients with one or two active GSTM1 alleles. The Ile/Ile GSTP1 genotype was observed in 37 (84/44%), the Ile/Val GSTP1 genotype in 38 (84/45.2%) patients and the Val/Val GSTP1 genotype in nine (84/10.7%) patients. There was no significant (P>0.05) association between the GST genotypes assessed and the frequency FAE responder status, except for the Val/Val GSTP1 polymorphism, which was a significant (overall model fit; P=0.0012) predictor for nonresponders with an odds ratio of 43.4 (95% confidence interval: 4.2-511.1). The coefficient of regression was 3.9, with a SE of 1.2 as assessed by logistic regression analysis (P=0.0017). The Val/Val GSTP1 polymorphism predicts nonresponders in FAE treatment of psoriasis patients and may therefore serve as a biomarker that enables a laboratory-based pretreatment selection of patients.

show abstract

“…HLA‐C*06 carriers with psoriasis have also had an increased, faster, and maintained response to ustekinumab compared to HLA‐C*06 non‐carriers . Instead, the HLA‐C genotype was not predictive of the treatment response to etanercept and/or adalimumab …”

Section: Discussionmentioning

confidence: 99%

HLA‐C and TNF gene polymorphisms are associated with psoriasis in Brazilian patients

et al. 2015

View full text Add to dashboard Cite

The strong association of HLA-C*06 allele with disease susceptibility, particularly in early onset psoriasis, indicates that younger ages could be considered to stratify psoriasis into early and late types. TNF -308 polymorphisms can be associated with psoriasis susceptibility and severity. Potential genetic markers of psoriasis in populations with a complex mixture of ethnicities should be investigated.

show abstract

Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis

Cited by 34 publications

References 20 publications

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

Val/Val glutathione-S-transferase P1 polymorphism predicts nonresponders in psoriasis patients treated with fumaric acid esters

HLA‐C and TNF gene polymorphisms are associated with psoriasis in Brazilian patients

Contact Info

Product

Resources

About